Litcius/Paper detail

Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis

Michelle Nadeau Nguyen, Melissa Reyes, S. Christopher Jones

2021JAMA Dermatology45 citationsDOIOpen Access PDF

Abstract

This case series study uses data from the FDA Adverse Event Reporting System to investigate a potential association between enfortumab vedotin treatment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.

Topics & Concepts

Toxic epidermal necrolysisMedicineDermatologyDrug reactionPharmacologyDrugDrug-Induced Adverse ReactionsAutoimmune Bullous Skin DiseasesNail Diseases and Treatments
Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis | Litcius